Global Type 2 Diabetes Market 2016-2020 - Low Diagnosis Rate Poses Challenge for Market - Research and Markets

04 Jul, 2016, 08:10 ET from Research and Markets

DUBLIN, July 4, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Type 2 Diabetes Market 2016-2020" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO )

The global type 2 diabetes drugs market is expected to grow at a CAGR of 7.28% during the period 2016-2020.

Diabetes, often referred to as diabetes mellitus, is a metabolic disease in which the patients' blood glucose levels remains high. Depending on the cause of development of diabetes, it can be divided into three types:

  • Type 1 diabetes (or insulin-dependent diabetes mellitus): In this condition, the pancreas do not produce the required amount of insulin, leading to high blood glucose levels.
  • Type 2 diabetes (non-insulin dependent diabetes mellitus): In this condition, though the body produces the required amount of insulin, the cells do not respond to it, increasing the glucose levels in the body.
  • Gestational diabetes: This condition occurs in pregnant women without any prior history of diabetes

The growing awareness of type 2 diabetes and the treatments available for it, as a result of national and global initiatives, drives the market. The increase in the diabetic population has increased accessibility to disease monitoring and disease management devices, and key vendors have begun to focus on emerging markets such as China.

According to the report, obesity, unhealthy diets, and lack of physical activity have increased the number of diabetes cases worldwide. As reported by WHO, it was estimated that 9% of the adults who are 18 years and above had diabetes in 2014. It was also reported that the global prevalence of diabetes would be around 366 million by 2030. In 2013, nearly 21 million live births were affected by diabetes during pregnancy. An increase in the exposure to the risk factors for type 2 diabetes in low- and middle-income groups is increasing in Middle East, North Africa, Southeast Asian, and Western Pacific regions.

Further, the report states that low diagnosis rate impedes people from availing the treatment, posing a challenge for the market.

Key vendors: 

  • AstraZeneca plc
  • Eli Lilly and Company
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Sanofi SA

Report Structure:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Disease overview

PART 06: Pipeline portfolio

PART 07: Market landscape

PART 08: Market segmentation by drug class

PART 09: Insulin

PART 10: DPP-4 inhibitors

PART 11: GLP-1 receptor agonists

PART 12: SGLT-2 inhibitors

PART 13: Geographical segmentation

PART 14: Market drivers

PART 15: Impact of drivers

PART 16: Market challenges

PART 17: Impact of drivers and challenges

PART 18: Market trends

PART 19: Vendor landscape

For more information visit http://www.researchandmarkets.com/research/3b8d4b/global_type_2


Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets